Shares of Compugen Ltd. jumped 44.5 percent Monday on news of a potential $540 million deal with Bayer Healthcare to develop antibody drugs for cancer immunotherapy, marking the Israeli firm's first substantial revenue-sharing drug development collaboration. Read More
LONDON – A new understanding of the molecular control of angiogenesis – the process by which new blood vessels grow – could lead to new therapies aimed at blocking tumor growth. Read More
Ixchelsis Ltd., a start-up with roots in Pfizer Inc.'s UK R&D facility at Sandwich, in Kent, has raised more than $14 million from TVM Life Science Ventures VII fund for development of an oxytocin antagonist, IX-01, for treating premature ejaculation. Read More
SHANGHAI – A year after China introduced an amended patent law, authorities have revoked the patent on Gilead Science Inc.'s HIV/AIDS and hepatitis B drug Viread (tenofovir disoproxil fumarate). Read More
LONDON – Cancer Research Technology Ltd. (CRT) agreed to its third licensing deal in six weeks, signing up Merck Serono SA to take forward compounds that block the WNT cell-signaling pathway. Read More
SHANGHAI – Still avoiding discussion of its failed bid for Onyx Pharmaceuticals Inc. in June, Amgen Inc. continues to implement an ambitious Asia expansion strategy when it announced the launch of a new collaboration with Japan's Teijin Pharma Ltd. to search for new therapies for autoimmune diseases. Read More
• KU Leuven, of Belgium, and FIT Biotech Oyj plc, of Tampere, Finland, signed a worldwide license and collaboration agreement to develop immunotherapeutics based on FIT's Gene Transport Unit technology for transient in vivo expression of monoclonal antibodies. Read More